Bringing a drug to market costs billions. Losing market share after launch costs even more. Yet too many pharmaceutical companies make critical commercial decisions -- pricing, positioning, messaging, lifecycle management -- on incomplete market understanding and outdated assumptions about prescriber behaviour. The gap between what your internal teams believe and what physicians, patients, and payers actually think is where launches underperform and brands lose ground.
Pharmaceutical market research from Meraki Research closes that gap. We deliver the primary data collection, analysis, and strategic insight that pharma and life sciences organizations need to make confident decisions from early-stage opportunity assessment through post-launch optimisation. Our work spans the full pharmaceutical lifecycle: pipeline prioritization, brand development & strategy, launch readiness, communication effectiveness testing, and in-market performance tracking.
We have supported research programs for branded therapies, generics, biosimilars, and specialty products across oncology, immunology, cardiology, neurology, and rare disease. Our team understands the regulatory, clinical, and commercial dynamics that make pharma research fundamentally different from general market research -- and we design every engagement to account for that complexity.
Why Pharmaceutical Research Demands Specialized Expertise
Pharmaceutical markets are shaped by forces that do not exist in most industries. Formulary decisions by a handful of PBMs can determine whether millions of patients have access to your therapy. A single competitor's clinical data readout can reshape prescriber attitudes overnight. Regulatory requirements constrain how you can communicate your product's value, even when the evidence is strong.
Generic research firms that lack pharma experience often miss these dynamics. They recruit the wrong physicians, ask questions that do not reflect clinical reality, or deliver findings that ignore the payer and regulatory context. The result is research that looks rigorous on paper but fails to inform the decisions that matter.
The stakes are too high for that kind of error. A misread of the prescriber landscape during pre-launch planning can lead to positioning that falls flat with your target audience. A communication effectiveness study that does not account for fair-balance requirements produces messaging that your MLR team rejects. A usage and attitudes study with an unverified physician sample produces performance metrics you cannot trust.
Our pharmaceutical practise is built for this environment. Every element of our methodology -- from respondent recruitment to analysis frameworks to deliverable design -- reflects the specific requirements of the pharma and life sciences sector.
Our Approach: Meraki Pharmaceutical Insights Engine
Our methodology addresses the full arc of pharmaceutical commercial decision-making. We work across the product lifecycle, adapting our approach to the specific questions and stakeholders relevant at each stage.
Phase 1 -- Therapeutic Landscape and Market Understanding
Every engagement begins with a deep dive into the therapeutic area. We synthesize published clinical data, competitive intelligence, epidemiological trends, and payer landscape analysis to build a comprehensive picture of the market your product operates in.
This is not a generic secondary research report. We focus on the strategic questions that will drive your primary research: Where are the unmet needs? What are the trends in treatment algorithms? How is the competitive set evolving? What opportunities exist for differentiation? How is the payer landscape shifting, and what evidence thresholds must a new therapy clear to win formulary access?
We also review published health economics and outcomes data to identify the evidence assets you can leverage in positioning -- and the evidence gaps that may require primary research to fill.
Phase 2 -- Stakeholder-Specific Data Collection
Pharmaceutical decisions are shaped by multiple audiences, and each requires a tailored research approach. Our data collection methods include:
- Prescribers (HCPs): We conduct depth interviews, online focus groups, and quantitative surveys with verified physicians and advanced-practise providers. Our moderators have clinical literacy -- they understand treatment protocols, formulary mechanics, and the realities of clinical practice. This means better rapport, better questions, and better data. We screen every HCP respondent against NPI databases and qualify for specialty, prescribing volume, and practise setting.
- Patients and Caregivers: We design patient research with IRB-level ethical standards, sensitivity-trained moderators, and recruitment strategies that reach beyond convenience samples. Our patient research captures the lived experience of disease and treatment -- the journey from symptoms through diagnosis, treatment initiation, adherence challenges, and long-term management -- in ways that inform both brand strategy and medical affairs.
- Payers and Market Access Stakeholders: We engage formulary decision-makers, pharmacy directors, and health economists to understand coverage criteria, usage requirements, and the evidence thresholds that drive tier placement and access. This research is essential for pricing strategy and market access planning.
- Key Opinion Leaders (KOLs): For early-stage or specialty products, we conduct structured KOL advisory boards and Delphi panels that inform clinical positioning and brand development & strategy. KOL research also helps identify potential advocates and advisory-board candidates for your medical affairs team.
Phase 3 -- Usage, Attitudes, and Brand Performance Assessment
For in-market products, our structured usage and attitudes framework provides a comprehensive diagnostic of how your brand is performing relative to the competition. We measure:
- Prescribing behaviour and treatment flow positioning
- Brand awareness, trial, and loyalty metrics
- Perceptual strengths and weaknesses versus competitors
- Satisfaction and unmet needs among current patients
- Switching triggers and barriers
- Share of voice and promotional effectiveness
This analysis is designed to surface actionable opportunities: where to reinforce strengths, where to close perceptual gaps, and where competitor vulnerability creates room to grow. For health and wellbeing categories that span the Rx-to-OTC spectrum -- including consumer brands competing for share of wallets in the wellness space -- we adapt the framework to account for consumer purchase dynamics, customer experience, and retail shelf presence alongside clinical factors.
Phase 4 -- Communication Effectiveness and Message Optimisation
We evaluate promotional materials, sales-aid content, DTC messaging, and medical-education communications against their target audiences. Our communication effectiveness testing measures:
- Message comprehension and recall
- Credibility and clinical relevance
- Emotional resonance and motivational impact
- Fair-balance perception and regulatory risk
- Competitive differentiation strength
Findings include specific optimisation recommendations -- not just "what scored well" but how to tailor interventions and refine messaging for maximum impact within the constraints of pharma marketing regulations. We work directly with your brand teams and, where appropriate, your MLR reviewers to ensure that research stimuli are compliant and findings are immediately actionable.
Phase 5 -- Strategic Synthesis and Commercial Roadmap
We integrate all research streams into a unified strategic narrative. Our deliverables do not just report findings; they connect insights to decisions. We identify the highest-priority opportunities, quantify the commercial impact of recommended actions, and provide a phased roadmap that your brand team can execute against.
The final deliverable is designed for executive audiences -- board presentations, brand-team offsites, and cross-functional planning sessions. We also provide detailed technical appendices with full data collection methodology, sample composition, and statistical documentation for teams that need to validate findings with medical affairs or regulatory colleagues.
When Pharmaceutical Market Research Is the Right Fit
Our pharmaceutical practise serves organizations across the life sciences value chain -- from global pharma to emerging biotech to specialty generics. Common use cases include:
- Pre-launch planning requiring market understanding, segmentation, positioning research, and message development.
- Launch readiness assessment validating that your commercial strategy, messaging, and market access plan are optimised before go-live.
- In-market brand performance tracking to monitor prescriber attitudes, patient satisfaction, and competitive dynamics over time.
- Communication effectiveness testing for promotional campaigns, medical education materials, and DTC creative.
- Lifecycle management research for line extensions, new indications, or loss-of-exclusivity planning.
- Market access and pricing research exploring payer attitudes, willingness-to-pay, and formulary positioning.
When it is NOT the right fit: If your research need is outside of pharmaceutical and life sciences markets, our general market research or consumer behaviour research capabilities may be more appropriate. We also do not conduct clinical trials or generate data intended for regulatory submission -- our work informs commercial and strategic decisions. For broader healthcare research that spans devices, digital health, and health systems in addition to pharma, our healthcare and pharma market research overview page describes the full scope of our practice.
What We Deliver
| Deliverable | Format | Description |
|---|---|---|
| Therapeutic Landscape Assessment | 40-60 page report | Market dynamics, competitive mapping, trends, and opportunity analysis |
| Usage & Attitudes Brand Study | Report + statistical appendix | Prescribing behaviour, brand performance metrics, and segmentation by HCP type |
| Communication Effectiveness Report | Presentation + data tables | Message and creative evaluation with optimisation recommendations |
| Patient Journey Map | Visual deliverable | End-to-end patient experience from diagnosis through treatment and adherence |
| Commercial Strategy Roadmap | Executive presentation | Prioritized recommendations with business-case support and phased milestones |
| Data Collection Summary | Technical appendix | Methodology, sample composition, and statistical notes for regulatory or medical-affairs review |
Timeline: Most pharmaceutical engagements run 10-16 weeks, depending on the number of audiences and the complexity of recruitment. Studies focused on a single audience (e.g., oncologists only) can often be completed in 8-10 weeks. We provide a detailed project plan at kickoff with milestone dates for every phase.
Industry Applications
- Branded Pharmaceuticals -- Launch strategy, in-market brand tracking, promotional optimisation, and lifecycle management research for innovator products across therapeutic areas.
- Specialty & Rare Disease -- KOL landscape mapping, patient journey research, and market-shaping strategies for products with small but high-value patient populations where every prescriber relationship matters.
- Generics & Biosimilars -- Prescriber and payer attitudes toward switching, formulary access strategies, and competitive positioning in commoditizing markets where price pressure and evidence requirements intersect.
- Biotech & Emerging Pharma -- Early-stage opportunity assessment, target-product-profile validation, and investor-ready market analysis for pre-revenue organizations. Our market research for small business practise supports emerging companies that need enterprise-grade research within growth-stage budgets.
- OTC & Consumer Health -- Usage and attitudes research for products transitioning from Rx to OTC, or consumer health and wellbeing brands competing on trust and efficacy in retail and DTC channels.
- Medical Affairs & HEOR -- Evidence-gap analysis, real-world evidence planning support, and value-proposition research for health economics and outcomes teams building the payer evidence strategy.